Omnicell Inc (OMCL)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $1.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Omnicell Inc (OMCL) Financials: Revenue, Profit and Cash Flow
Omnicell reported revenue of $1.18B for the fiscal year ended Dec 31, 2025, up 6.5% from the year before. That year, net income was $2.05M with a net margin of 0.2%, operating cash flow was $127.30M and free cash flow was $86.89M. The quarter ended Sep 30, 2026 had revenue of $307.85M and net income of $11.04M.
Revenue and Margins
The operating margin was 0.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $695.91M, a compound annual rate of 6.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.18B | +6.5% | 42.5% | 0.4% | 0.2% |
| Dec 2024 | $1.11B | -3.0% | 42.3% | 0.0% | 1.1% |
| Dec 2023 | $1.15B | -11.5% | 43.3% | -3.0% | -1.8% |
| Dec 2022 | $1.30B | +14.5% | 45.4% | -0.2% | 0.4% |
| Dec 2021 | $1.13B | +26.9% | 49.0% | 7.9% | 6.9% |
| Dec 2020 | $892.21M | -0.5% | 46.3% | 4.0% | 3.6% |
| Dec 2019 | $897.03M | +13.9% | 48.7% | 8.7% | 6.8% |
| Dec 2018 | $787.31M | +10.5% | 47.3% | 5.6% | 4.8% |
| Dec 2017 | $712.71M | +2.4% | 44.7% | 1.6% | 4.3% |
| Dec 2016 | $695.91M | N/A | 45.6% | 3.1% | 1.4% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 83.6% from the year before. In the quarter ended Sep 2026, net income rose 102.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18B | $1.11B | $1.15B | $1.30B | $1.13B | $892.21M | $897.03M | $787.31M | $712.71M | $695.91M |
| Cost of revenue | $681.40M | $641.24M | $650.27M | $706.96M | $577.37M | $478.92M | $460.12M | $414.98M | $394.08M | $378.82M |
| Gross profit | $503.44M | $471.00M | $496.84M | $588.99M | $554.65M | $413.29M | $436.91M | $372.33M | $318.64M | $317.08M |
| Research and development | $88.67M | $90.41M | $97.11M | $104.97M | $75.72M | $70.16M | $68.64M | $64.84M | $66.02M | $57.80M |
| Operating income | $5.16M | $337.00K | -$34.87M | -$2.32M | $89.51M | $35.53M | $78.35M | $44.39M | $11.14M | $21.41M |
| Net income | $2.05M | $12.53M | -$20.37M | $5.65M | $77.85M | $32.19M | $61.34M | $37.73M | $30.52M | $9.76M |
| EBITDA | $100.61M | $119.14M | $79.85M | $100.88M | $172.99M | $107.31M | $140.26M | $89.26M | $57.61M | $72.93M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $307.85M | $312.21M | $309.88M | $313.98M | $310.63M | $290.56M | $269.67M | $306.88M | $282.42M | $276.79M | $246.15M | $258.85M |
| Gross profit | $137.83M | $152.94M | $140.36M | $130.32M | $134.50M | $127.68M | $110.94M | $141.76M | $122.27M | $114.35M | $92.62M | $105.40M |
| Operating income | $14.93M | $32.45M | $16.85M | $415.00K | $8.24M | $8.12M | -$11.62M | $12.40M | $6.56M | $3.22M | -$21.85M | -$23.36M |
| Net income | $11.04M | $24.29M | $11.36M | -$2.03M | $5.46M | $5.64M | -$7.02M | $15.84M | $8.63M | $3.73M | -$15.68M | -$14.38M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $179.55M by $16.97M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.97B | $2.12B | $2.23B | $2.21B | $2.14B | $1.82B | $1.24B | $1.08B | $1.02B | $935.10M |
| Current assets | $680.07M | $815.49M | $927.57M | $881.81M | $780.70M | $829.41M | $483.24M | $397.13M | $352.27M | $315.41M |
| Cash and equivalents | $196.52M | $369.20M | $467.97M | $330.36M | $349.05M | $485.93M | $127.21M | $67.19M | $32.42M | $54.49M |
| Total liabilities | $742.91M | $877.65M | $1.04B | $1.08B | $995.81M | $857.00M | $395.56M | $401.63M | $462.02M | $503.50M |
| Short-term debt | $11.96M | $174.32M | $0 | $10.76M | $488.15M | $0 | $10.06M | $8.99M | $15.21M | $8.41M |
| Long-term debt | $167.60M | $166.40M | $569.66M | $566.57M | $0 | $467.20M | $50.00M | $135.42M | $194.92M | $245.73M |
| Shareholder equity | $1.23B | $1.24B | $1.19B | $1.13B | $1.15B | $967.50M | $845.25M | $679.62M | $554.34M | $431.61M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.06B | $2.00B | $2.00B | $1.97B | $1.95B | $2.15B | $2.15B | $2.12B | $2.30B | $2.29B | $2.28B | $2.23B |
| Total liabilities | $739.58M | $707.25M | $747.48M | $742.91M | $727.70M | $881.88M | $894.37M | $877.65M | $1.07B | $1.09B | $1.10B | $1.04B |
| Cash and equivalents | $314.86M | $292.17M | $239.22M | $196.52M | $180.05M | $399.00M | $386.83M | $369.20M | $570.63M | $556.78M | $512.36M | $467.97M |
| Shareholder equity | $1.32B | $1.29B | $1.26B | $1.23B | $1.22B | $1.26B | $1.26B | $1.24B | $1.23B | $1.20B | $1.19B | $1.19B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 68.3% of operating cash flow. Share repurchases came to 89.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $127.30M | $187.72M | $181.09M | $77.78M | $231.81M | $185.87M | $145.01M | $103.97M | $24.83M | $49.90M |
| Capital expenditures | $40.41M | $36.46M | $41.47M | $47.54M | $28.97M | $22.84M | $15.89M | $23.70M | $15.34M | $13.45M |
| Free cash flow | $86.89M | $151.26M | $139.62M | $30.25M | $202.84M | $163.03M | $129.11M | $80.27M | $9.49M | $36.45M |
| Dividends paid | N/A | N/A | $4.40M | N/A | N/A | $105.56M | $9.67M | N/A | $0 | $0 |
| Share repurchases | $77.60M | $0 | $0 | $52.21M | $0 | $53.03M | $0 | $0 | N/A | N/A |
| Investing cash flow | -$60.36M | -$52.79M | -$55.02M | -$58.67M | -$412.50M | -$279.87M | -$61.66M | -$54.37M | -$34.99M | -$341.32M |
| Financing cash flow | -$218.32M | -$235.58M | $23.42M | -$20.95M | $47.36M | $456.27M | -$23.48M | -$13.60M | -$9.88M | $263.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.05M | $68.31M | $54.50M | $30.35M | $28.27M | $42.76M | $25.92M | $56.31M | $22.75M | $58.70M | $49.95M | $38.41M |
| Capital expenditures | $11.36M | $8.94M | $12.44M | $7.71M | $9.75M | $11.78M | $11.17M | $9.09M | $8.87M | $9.55M | $8.96M | $9.07M |
| Free cash flow | $21.69M | $59.37M | $42.06M | $22.64M | $18.51M | $30.97M | $14.75M | $47.23M | $13.89M | $49.15M | $41.00M | $29.34M |
Frequently Asked Questions About OMCL
What is Omnicell's annual revenue?
Omnicell reported revenue of $1.18B for the fiscal year ended Dec 31, 2025.
How fast is Omnicell's revenue growing?
Revenue was up 6.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.9%.
Is Omnicell profitable?
Yes. Omnicell reported net income of $2.05M for the fiscal year ended Dec 31, 2025, with a net margin of 0.2%.
How much free cash flow does OMCL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $127.30M minus capital expenditures of $40.41M produced free cash flow of $86.89M.
How much debt does Omnicell have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $167.60M, short-term debt of $11.96M and cash and equivalents of $196.52M.
OMCL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts